Of note, we found that DLBCL in Cluster_2 enriched for JAK2/PD-L2 amplification had less frequency of MYD88_L265P mutation (12.5%, 1/8) (Fig. 1a, Table 4), which was supported by the Cancer Genome Atlas data (TCGA, PanCancer Atlas) from cBioPortal [8, 9] (Fig. 1c). This evidence concerns the gene MYD88 and diffuse large B-cell lymphoma.